Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Spero Therapeutics Inc (SPRO)

Spero Therapeutics Inc (SPRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,697
  • Shares Outstanding, K 27,187
  • Annual Sales, $ 18,150 K
  • Annual Income, $ -60,930 K
  • 60-Month Beta 1.68
  • Price/Sales 33.76
  • Price/Cash Flow N/A
  • Price/Book 3.83
Trade SPRO with:

Options Overview

Details
  • Implied Volatility 98.03%
  • Historical Volatility 53.69%
  • IV Percentile 19%
  • IV Rank 2.64%
  • IV High 1,183.90% on 03/16/20
  • IV Low 68.57% on 09/22/20
  • Put/Call Vol Ratio 0.21
  • Today's Volume 68
  • Volume Avg (30-Day) 243
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 870
  • Open Int (30-Day) 1,535

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -0.77
  • Number of Estimates 4
  • High Estimate -0.65
  • Low Estimate -0.97
  • Prior Year -1.32
  • Growth Rate Est. (year over year) +41.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.02 +29.60%
on 02/05/21
22.24 -18.28%
on 02/08/21
-0.49 (-2.63%)
since 01/26/21
3-Month
14.02 +29.60%
on 02/05/21
23.64 -23.14%
on 12/28/20
+2.25 (+14.13%)
since 11/25/20
52-Week
5.25 +246.10%
on 03/16/20
23.64 -23.14%
on 12/28/20
+8.62 (+90.26%)
since 02/26/20

Most Recent Stories

More News
Spero Therapeutics to Present at Investor Conferences in March

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics (SPRO) Sees Hammer Chart Pattern: Time to Buy?

Spero Therapeutics (SPRO) has been struggling lately, but the selling pressure may be coming to an end soon.

SPRO : 18.17 (-1.14%)
Spero Therapeutics Announces Issuance of Allowance for a U.S. Patent Covering Lead Candidate Tebipenem HBr

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Announces Appointment of Sath Shukla as Chief Financial Officer

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Added to the NASDAQ Biotechnology Index

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
IBB : 156.93 (-0.14%)
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...

SPRO : 18.17 (-1.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 20.14
2nd Resistance Point 19.51
1st Resistance Point 18.84
Last Price 18.17
1st Support Level 17.54
2nd Support Level 16.91
3rd Support Level 16.24

See More

52-Week High 23.64
Last Price 18.17
Fibonacci 61.8% 16.61
Fibonacci 50% 14.44
Fibonacci 38.2% 12.27
52-Week Low 5.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar